Jason Jakob Lohmueller

Title: Jason Jakob Lohmueller: Advancing Programmable Antigen-Targeting

Introduction

Jason Jakob Lohmueller is an inventor based in Pittsburgh, Pennsylvania. His work includes innovations in chimeric antigen receptors (CARs), an area of research focused on engineering immune cells to recognize and target specific antigens.

Latest Patents

Lohmueller’s listed patent work includes “Covalent Adaptor SynNotch and Chimeric Antigen Receptors (CARs) for Programmable Antigen-Targeting.” One disclosed invention is an affinity-enhanced monomeric streptavidin CAR. It combines an extracellular high-affinity streptavidin component with a CD8 hinge, a CD28 transmembrane domain, intracellular 4-1BB and/or CD28 signaling domains, and a CD3 zeta signaling domain.

The disclosure also covers nucleic acids encoding the CAR, transformed T cells and natural killer (NK) cells, and potential use of the engineered receptor in tumor treatment. Lohmueller is associated with University of Pittsburgh. His listed portfolio includes 2 patents.

Career Highlights

Lohmueller’s patent-related work reflects research into programmable approaches to antigen targeting and engineered immune-cell therapies. The described CAR design brings together receptor components and signaling domains intended to support recognition and cellular response.

Collaborations

Lohmueller’s listed coworker is Alexander Deiters. Their research connection is associated with the University of Pittsburgh and work involving programmable antigen-targeting technologies.

Conclusion

Jason Jakob Lohmueller’s listed inventions focus on engineered CARs and their potential application in tumor treatment, contributing to research on programmable immune-cell therapies.